Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
Ram Gupta,1 Anita R Chaudhary,2 Binita N Shah,1 Avinash V Jadhav,3 Shitalkumar P Zambad,1 Ramesh Chandra Gupta,4 Shailesh Deshpande,4 Vijay Chauthaiwale,4 Chaitanya Dutt4 1Department of Pharmacology, 2Cellular and Molecular Biology, 3Preclinical Safety Evaluation, 4Discovery, Torrent Research Centr...
Main Authors: | Gupta R, Chaudhary AR, Shah BN, Jadhav AV, Zambad SP, Gupta RC, Deshpande S, Chauthaiwale V, Dutt C |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-01-01
|
Series: | Clinical and Experimental Gastroenterology |
Online Access: | http://www.dovepress.com/therapeutic-treatment-with-a-novel-hypoxia-inducible-factor-hydroxylas-a15614 |
Similar Items
-
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
by: Zambad SP, et al.
Published: (2013-12-01) -
TRC120038, a Novel Dual AT1/ETA Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats
by: Anookh Mohanan, et al.
Published: (2011-01-01) -
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
by: Shitalkumar P Zambad, et al.
Published: (2011-01-01) -
Effect of TRC and F/TRC Strengthening on the Cracking Behaviour of RC Beams in Bending
by: Edoardo Rossi, et al.
Published: (2021-08-01) -
The FRP and TRC strengthening of the masonry structures
by: Granovsky Arkady, et al.
Published: (2019-01-01)